help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Crawford, E. D.
Right arrow Articles by DeAntoni, E. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Crawford, E. D.
Right arrow Articles by DeAntoni, E. P.

Journal of Clinical Endocrinology & Metabolism, Vol 80, 1062-1066, Copyright © 1995 by Endocrine Society

ARTICLES

Current status of combined androgen blockade: optimal therapy for advanced prostate cancer [published erratum appears in J Clin Endocrinol Metab 1995 Jul;80(7):2056]

ED Crawford and EP DeAntoni
University of Colorado, Denver, USA.

CAB represents the gold standard of treatment for patients with advanced prostate cancer. The treatment is well-tolerated with the only increased side effect being a 6% increase in diarrhea. Ninety-five percent of patients benefit, and those having minimal metastatic disease show a marked benefit. Since maximal androgen blockade seems to be of major benefit for patients with good performance status and minimal disease, its role needs to be investigated in patients with earlier stages of prostate cancer including stages B, C, and D1. Important trials are underway to address these provocative issues. Progress in the treatment of patients who relapse with metastatic prostate cancer after initial CAB will probably come to rely on the discovery and development of novel drugs or innovative drug delivery systems. Immunomodulatory drugs to enhance the body's natural defenses, monoclonal antibodies directed against prostate specific cellular antigens and tagged with radioisotopes or cytotoxic agents, and bone- seeking radiopharmaceuticals may represent the breakthrough that is needed. Exciting advances in gene therapy may represent the ultimate chance for a cure.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
T. Kvorning, M. Andersen, K. Brixen, and K. Madsen
Suppression of endogenous testosterone production attenuates the response to strength training: a randomized, placebo-controlled, and blinded intervention study
Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1325 - E1332.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
R. M. Moretti, M. Montagnani Marelli, J. C. Van Groeninghen, and P. Limonta
Locally Expressed LHRH Receptors Mediate the Oncostatic and Antimetastatic Activity of LHRH Agonists on Melanoma Cells
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3791 - 3797.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Montagnani Marelli, R. M. Moretti, D. Dondi, M. Motta, and P. Limonta
Luteinizing Hormone-Releasing Hormone Agonists Interfere with the Mitogenic Activity of the Insulin-Like Growth Factor System in Androgen-Independent Prostate Cancer Cells
Endocrinology, January 1, 1999; 140(1): 329 - 334.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1995 by The Endocrine Society